Julie K. Hagan

Julie K. Hagan, MS, currently serves as the Vice President of Regulatory Affairs at Korro Bio, Inc., beginning in July 2024. Prior to this role, Julie held the position of Vice President, Global Regulatory Affairs at Tune Therapeutics and Vice President, Regulatory Affairs at eGenesis, Inc. Notably, Julie was the US Regulatory Affairs Lead for Orchard Therapeutics' OTL-200 ex vivo gene therapy program for Metachromatic Leukodystrophy. Julie also brings extensive experience from roles at Apic Bio, Halloran Consulting Group, REGENXBIO Inc., Mallinckrodt Pharmaceuticals, Human Genome Sciences, and ICON plc, contributing to various regulatory affairs initiatives across diverse biopharmaceutical projects. Julie's academic background includes a Master of Science in Biotechnology from The Johns Hopkins University and a Bachelor of Arts in Biology from Gettysburg College.